BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Entrectinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Entrectinib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04302025-2220@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Entrectinib: Phase 2 readout est. (NCT04302025)
DESCRIPTION:Entrectinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Multiple Therapies in Biomarker-selected Participants With Resecta
 ble Stages IB-III Non-small Cell Lung Cancer (NSCLC)\nEstimated primary co
 mpletion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/entrectinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04302025
URL:https://assetmemo.bio/drug/entrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05170204-2220@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270120
SUMMARY:Entrectinib: Phase 3 readout est. (NCT05170204)
DESCRIPTION:Entrectinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts o
 f Participants With Locally Advanced\, Unresectable\, Stage III Non-Small 
 Cell Lung Cancer (NSCLC)\nEstimated primary completion: 19 January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/entrectinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05170204
URL:https://assetmemo.bio/drug/entrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02650401-2220@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Entrectinib: Phase 1/2 readout est. (NCT02650401)
DESCRIPTION:Entrectinib\, phase 1/2.\nStudy: Study Of Entrectinib (Rxdx-101
 ) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or
  Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options\nEst
 imated primary completion: 30 June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/entrectinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT02650401
URL:https://assetmemo.bio/drug/entrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-2220@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Entrectinib: Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Entrectinib\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies 
 as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)\nEs
 timated primary completion: 30 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/entrectinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT03178552
URL:https://assetmemo.bio/drug/entrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-2220@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Entrectinib: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Entrectinib\, phase 2.\nStudy: The Drug Rediscovery Protocol (D
 RUP Trial)\nEstimated primary completion: September 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/entrectinib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/entrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06528691-2220@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Entrectinib: Phase 2 readout est. (NCT06528691)
DESCRIPTION:Entrectinib\, phase 2.\nStudy: Entrectinib as a Single Agent in
  Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED
  CNS Tumors\nEstimated primary completion: November 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/entrectinib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06528691
URL:https://assetmemo.bio/drug/entrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692491-2220@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Entrectinib: Phase 2 readout est. (NCT06692491)
DESCRIPTION:Entrectinib\, phase 2.\nStudy: Study of Precision Treatment for
  Rare Tumours in China Guided by PDO and NGS\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 ntrectinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06692491
URL:https://assetmemo.bio/drug/entrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05770544-2220@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Entrectinib: Phase 2/3 readout est. (NCT05770544)
DESCRIPTION:Entrectinib\, phase 2/3.\nStudy: DETERMINE Trial Treatment Arm 
 03: Entrectinib in Adult\, Paediatric and Teenage/Young Adult Patients Wit
 h ROS1 Gene Fusion-Positive Cancers.\nEstimated primary completion: Octobe
 r 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/entrectinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05770
 544
URL:https://assetmemo.bio/drug/entrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05722886-2220@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Entrectinib: Phase 2/3 readout est. (NCT05722886)
DESCRIPTION:Entrectinib\, phase 2/3.\nStudy: DETERMINE (Determining Extende
 d Therapeutic Indications for Existing Drugs in Rare Molecularly Defined I
 ndications Using a National Evaluation Platform Trial) - Master Screening 
 Protocol\nEstimated primary completion: October 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/entrectinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05722886
URL:https://assetmemo.bio/drug/entrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05159245-2220@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20311125
DTEND;VALUE=DATE:20311126
SUMMARY:Entrectinib: Phase 2 readout est. (NCT05159245)
DESCRIPTION:Entrectinib\, phase 2.\nStudy: The Finnish National Study to Fa
 cilitate Patient Access to Targeted Anti-cancer Drugs\nEstimated primary c
 ompletion: 25 November 2031. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/entrectinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05159245
URL:https://assetmemo.bio/drug/entrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04589845-2220@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20320925
DTEND;VALUE=DATE:20320926
SUMMARY:Entrectinib: Phase 2 readout est. (NCT04589845)
DESCRIPTION:Entrectinib\, phase 2.\nStudy: Tumor-agnostic Precision Immuno-
 oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study\
 nEstimated primary completion: 25 September 2032. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/entrectinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04589845
URL:https://assetmemo.bio/drug/entrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05862285-2220@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20330301
DTEND;VALUE=DATE:20330302
SUMMARY:Entrectinib: Phase 3 readout est. (NCT05862285)
DESCRIPTION:Entrectinib\, phase 3.\nStudy: A Rollover Study for Participant
 s Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored 
 Study\nEstimated primary completion: 1 March 2033. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/entrectinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05862285
URL:https://assetmemo.bio/drug/entrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07916389-2220@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20341130
DTEND;VALUE=DATE:20341201
SUMMARY:Entrectinib: Phase 2 readout est. (NCT07916389)
DESCRIPTION:Entrectinib\, phase 2.\nStudy: Molecularly Stratified Trial for
  Newly Diagnosed Infant-Type Hemispheric Glioma\nEstimated primary complet
 ion: November 2034. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 ntrectinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07916389
URL:https://assetmemo.bio/drug/entrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
